Skip to main content
Premium Trial:

Request an Annual Quote

Arthur Patterson, Ron Zimmerman, Katarina Alenäs, John Lindsay

Premium
Elona BioTechnologies this week named Arthur Patterson its CEO, replacing Ron Zimmerman, who will continue at the company as chairman.
 
Patterson was previously executive director of the Flagship Enterprise Center, a business and technology incubation center in Anderson, Ind. He also held various marketing, sales, and business development posts at GE, Ethyl Corp., and Tetra Technologies.
 
Based in Greenwood, Ind., Elona offers protein-purification and –characterization services.
 

 
Swedish sample preparation product firm Denator said this week Katarina Alenäs has joined the firm as its European sales director. Alenäs has held sales, marketing, and product management positions at Agilent Technologies, Bayer Healthcare Diagnostics, and Aventis during the past decade.
 
In the US, the company will be represented by John Lindsay, president of SciPartners, a manufacturer’s representative agency.
 
Based in Gothenburg, Denator will launch its first commercial system for instant tissue stabilization at the annual conference of the Human Proteome Organization next month.  

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.